Babies playing with toys.
Dosing and administration

Bexsero offers flexible dosing options, allowing for integration into the routine vaccination schedule1

Dosing schedule

Bexsero offers flexible dosing options for the broad population¹

Table to show Bexsero dosing options for each age group Table to show Bexsero dosing options for each age group

ᵃFirst dose should be given no earlier than 2 months of age. The safety and efficacy of Bexsero in infants less than 8 weeks of age has not yet been established. No data are available.
ᵇIn case of delay, the booster should not be given later than 24 months of age.
ᶜThe need for, and timing of, further booster doses has not yet been determined.
ᵈNo data are available for adults above 50 years of age.

Administration¹

  • Bexsero is given by deep intramuscular injection preferably in:
    • The anterolateral aspect of the thigh in infants
    • The deltoid muscle region of the upper arm in older patients
  • Separate injection sites must be used if more than one vaccine is administered at the same time
  • The vaccine must not be injected intravenously, subcutaneously, or intradermally and must not be mixed with other vaccines in the same syringe

As with many vaccines, healthcare professionals should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of antipyretics at the time of or closely after vaccination can reduce the incidence and intensity of postvaccination febrile reactions. Antipyretic medication should be initiated according to local guidelines in infants and children (less than 2 years of age).

An infant being vaccinated

Co-administration with Bexsero

Bexsero can be co-administered with any of the following vaccine antigens, either as a monovalent or as combination vaccines¹:

  • Diphtheria
  • Tetanus
  • Acellular pertussis
  • Haeomophilus influenzae type b
  • Inactivated poliomyelitis
  • Hepatitis B
  • Heptavalent pneumococcal conjugate
  • Measles
  • Mumps
  • Rubella
  • Varicella
  • Meningococcal groups A, C, W, Y conjugate

Clinical studies suggest there is no clinically relevant immunological interference when Bexsero is given concomitantly with routine infant vaccines¹,³

A mother holding her newborn son

Formulation¹

Bexsero is available as a white opalescent liquid suspension for injection in a prefilled syringe and comes as a 0.5-ml dose.

A pack of Bexsero with syringe

Storage and stability¹

  • Shelf life: 3 years
  • Store in a refrigerator (2°C–8°C)
  • Do not freeze
  • Store in the original package in order to protect from light
  • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
  • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension
A Bexsero syringe
  • ADMINISTRATION

    Administration¹

    An infant being vaccinated
    • Bexsero is given by deep intramuscular injection preferably in:
      • The anterolateral aspect of the thigh in infants
      • The deltoid muscle region of the upper arm in older patients
    • Separate injection sites must be used if more than one vaccine is administered at the same time
    • The vaccine must not be injected intravenously, subcutaneously, or intradermally and must not be mixed with other vaccines in the same syringe

    As with many vaccines, healthcare professionals should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of antipyretics at the time of or closely after vaccination can reduce the incidence and intensity of postvaccination febrile reactions. Antipyretic medication should be initiated according to local guidelines in infants and children (less than 2 years of age).

  • CO-ADMINISTRATION

    Co-administration with Bexsero

    A mother holding her newborn son

    Bexsero can be co-administered with any of the following vaccine antigens, either as a monovalent or as combination vaccines¹:

    • Diphtheria
    • Tetanus
    • Acellular pertussis
    • Haeomophilus influenzae type b
    • Inactivated poliomyelitis
    • Hepatitis B
    • Heptavalent pneumococcal conjugate
    • Measles
    • Mumps
    • Rubella
    • Varicella
    • Meningococcal groups A, C, W, Y conjugate

    Clinical studies suggest there is no clinically relevant immunological interference when Bexsero is given concomitantly with routine infant vaccines¹,³

  • FORMULATION

    Formulation¹

    A pack of Bexsero with syringe

    Bexsero is available as a white opalescent liquid suspension for injection in a prefilled syringe and comes as a 0.5-ml dose.

  • STORAGE AND STABILITY

    Storage and stability¹

    A Bexsero syringe
    • Shelf life: 3 years
    • Store in a refrigerator (2°C–8°C)
    • Do not freeze
    • Store in the original package in order to protect from light
    • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
    • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension

References:

  1. Bexsero Summary of Product Characteristics. GSK Vaccines S.r.l.; 2020.
  2. Pfizer Ltd. Trumenba. Annex I; Summary of Product Characteristics. EMA; May 2018.
  3. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–582.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

L.K January 2021 PM-GB-BEX-WCNT-200003